Irritable bowel syndrome: low dose antidepressant improves symptoms

Helen Saul; Samantha Cassidy; Laura Swaithes; Alexander C Ford

doi:10.1136/bmj.q871

Irritable bowel syndrome: low dose antidepressant improves symptoms

BMJ. 2024 May 1:385:q871. doi: 10.1136/bmj.q871.

Authors

Helen Saul¹, Samantha Cassidy¹, Laura Swaithes¹, Alexander C Ford²

Affiliations

¹ NIHR Evidence, Twickenham, UK.
² University of Leeds.

PMID: 38692664
DOI: 10.1136/bmj.q871

Abstract

The studyFord AC, Wright-Hughes A, Alderson SL, et al. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;402:1773-85.To read the full NIHR Alert, go to: https://evidence.nihr.ac.uk/alert/irritable-bowel-syndrome-low-dose-antidepressant-improves-symptoms/.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

MeSH terms

Amitriptyline* / administration & dosage
Amitriptyline* / therapeutic use
Antidepressive Agents / administration & dosage
Antidepressive Agents / therapeutic use
Antidepressive Agents, Tricyclic / administration & dosage
Antidepressive Agents, Tricyclic / therapeutic use
Clinical Trials, Phase III as Topic
Double-Blind Method
Humans
Irritable Bowel Syndrome* / drug therapy
Randomized Controlled Trials as Topic
Treatment Outcome

Substances

Amitriptyline
Antidepressive Agents
Antidepressive Agents, Tricyclic